Holen Sie sich die Stockscreener-App
6.54
2.19%
0.14
Handel nachbörslich:
6.64
0.10
+1.53%
Schlusskurs vom Vortag:
$6.40
Offen:
$6.51
24-Stunden-Volumen:
37.03M
Relative Volume:
1.41
Marktkapitalisierung:
$2.61B
Einnahmen:
$64.60M
Nettoeinkommen (Verlust:
$-377.75M
KGV:
-4.2194
EPS:
-1.55
Netto-Cashflow:
$-335.64M
1W Leistung:
+25.29%
1M Leistung:
+30.02%
6M Leistung:
-12.68%
1J Leistung:
-19.66%
1-Tages-Spanne:
$6.0911
$6.56
1-Wochen-Bereich:
$5.205
$7.15
52-Wochen-Spanne:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Firmenname
Recursion Pharmaceuticals Inc
Sektor
Branche
Telefon
(385) 269-0203
Adresse
41S RIO GRANDE STREET, SALT LAKE CITY
Vergleichen Sie RXRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
6.54 | 2.26B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Eingeleitet | Needham | Buy |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-04 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Eingeleitet | Berenberg | Buy |
| 2021-05-11 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Eingeleitet | JP Morgan | Neutral |
| 2021-05-11 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
Is Recursion Pharmaceuticals Inc. a good long term investmentFree Investment Case Studies - jammulinksnews.com
What drives Recursion Pharmaceuticals Inc. stock priceRapid growth trajectories - jammulinksnews.com
Recursion Pharmaceuticals Trading Volume Drops 52.75% to $23.7 Million, Ranks 464th in Market - AInvest
Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia - MSN
Recursion Pharmaceuticals (RXRX) Jumps 9.6% Ahead of Q2 Earnings - Insider Monkey
Recursion Pharmaceuticals Sees Sharp Gain on AI Biotech Optimism - FinancialContent
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Yahoo.co
What analysts say about Recursion Pharmaceuticals Inc. stockOver 200% growth - jammulinksnews.com
Top 2 Health Care Stocks You May Want To Dump This Quarter - Benzinga
(RXRX) Trading Signals - news.stocktradersdaily.com
Here's Why Shares in Recursion Pharmaceuticals Surged Today - AOL.com
Recursion Pharmaceuticals Surges 58.77% in Trading Volume Reaching 207th Position in Market Rankings - AInvest
History of Recursion Pharmaceuticals, Inc.: AI‑Driven Drug Discovery Beginnings (NASDAQ:RXRX) - FinancialContent
Recursion Pharmaceuticals Options Trading: A Deep Dive into Market Sentiment - Nasdaq
Recursion Pharmaceuticals Stock (RXRX) Opinions on Recent Price Surge - Nasdaq
Recursion Pharmaceuticals’ Stock Soars as It Gains Full Rights to REV102 - StocksToTrade
Recursion Pharmaceuticals Surges 5.8%: Will Momentum Continue? - AInvest
Why Is Recursion Pharma Stock Surging On Monday? - Benzinga
Recursion Pharmaceuticals (RXRX) Stock Jumps After Acquiring Full Rights to REV102 for Rare Bone Disorder - FinancialBuzz.com
Recursion Pharmaceuticals Stock Soars Amid Investor Optimism - TipRanks
Recursion Pharmaceuticals (RXRX) Soars 5.8%: Is Further Upside Left in the Stock? - Yahoo Finance
Recursion Bets On AI Drug Discovery Despite Volatile Year - Finimize
Recursion Pharmaceuticals Inc. Stock Analysis and ForecastExtraordinary performance - Autocar Professional
Recursion Pharmaceuticals (RXRX) Sees 14% Price Surge Over Last Month - Yahoo Finance
Recursion Pharmaceuticals Experiences Surge in Bullish Options Activity with Implied Volatility Rising 9 Points to 110.01%. - AInvest
Recursion Pharmaceuticals (RXRX) Is Up 10.6% After Expanding AI Partnerships and Acquiring Exscientia - simplywall.st
Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug - MSN
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
Recursion Pharmaceuticals Surges to 360th in Market Rankings with $312 Million Trading Volume - AInvest
Recursion Pharmaceutical’s Latest Acquisition: A Game Changer? - timothysykes.com
Why Did Recursion Soar 12%? - timothysykes.com
10 Best Small Cap AI Stocks to Buy According to Analysts - Insider Monkey
Recursion Pharmaceuticals Soars After Strategic Acquisition - StocksToTrade
Why Recursion Pharmaceuticals Stock is Climbing - TipRanks
Recursion Pharmaceuticals Acquires Full Rights to REV102, Bolstering Stock Performance - timothysykes.com
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process? - MSN
Recursion Pharmaceuticals (RXRX) Rises Higher Than Market: Key Facts - MSN
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock - MSN
Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia - Yahoo.co
Recursion Pharmaceuticals Sees Elevated Call Volume and Implied Volatility - AInvest
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? - The Globe and Mail
With 68% institutional ownership, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a favorite amongst the big guns - simplywall.st
Recursion Pharmaceuticals call volume above normal and directionally bullish - TipRanks
RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates - MSN
Morgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating - MSN
Jensen Huang's Nvidia Owns 6 Stocks. Here's the Best of the Bunch. - The Motley Fool
Finanzdaten der Recursion Pharmaceuticals Inc-Aktie (RXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):